Screener
Bicara Therapeutics BCAX EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Bicara Therapeutics’s reported figures.
The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026. Open the filing →
- Filed
- May 11, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033429
FAQ
- What is Bicara Therapeutics's EBITDA?
- Bicara Therapeutics (BCAX) reported EBITDA of -$60.2M in Q1 2026.
- How has Bicara Therapeutics's EBITDA changed year-over-year?
- Bicara Therapeutics's EBITDA decreased by 44.1% year-over-year, from -$41.77M to -$60.2M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Bicara Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude